Latest On Selecta Biosciences, Inc (SELB):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-05 05:09 EST | News | Selecta Biosciences, Inc. (SELB) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-04 16:25 EST | News | Selecta Biosciences GAAP EPS of -$0.14 misses by $0.05, revenue of $5.9M misses by $6.24M | N/A | |
| 2023-04-08 14:57 EST | News | Selecta's New Gout Data Strengthens Evidence Of Inadequate Differentiation | N/A | |
| 2023-03-21 09:36 EST | News | Selecta surges ~20% as gout drug SEL-212 meets main goal in 2 phase 3 trials | N/A | |
| 2023-03-14 09:38 EST | News | Murky Forecast For Selecta Biosciences' SEL-212 In Treating Chronic Refractory Gout | N/A | |
About Selecta Biosciences, Inc (SELB):
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylm read more...alonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
General
- Name Selecta Biosciences, Inc
- Symbol SELB
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 43
- Fiscal Year EndDecember
- IPO Date2016-06-22
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://selectabio.com
Valuation
- Price/Sales (Trailing 12 Mt.) 30.14
- Price/Book (Most Recent Quarter) 31.26
- Enterprise Value Revenue 24.65
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.29
- Next Year EPS Estimate -$0.40
- Next Quarter EPS Estimate -$0.11
- Operating Margin -342%
- Return on Assets -27%
- Revenue 16.6 million
- Earnings Per Share -$1.85
- Revenue Per Share $0.16
- Gross Profit -37908000
- Quarterly Earnings Growth 79.6%
Highlights
- Market Capitalization 510.74 million
- EBITDA -57785000
- Analyst Target Price $8
- Book Value Per Share $0.10
Share Statistics
- Shares Outstanding 112.37 million
- Shares Float 84.23 million
- % Held by Insiders 2604%
- % Held by Institutions 64.41%
- Shares Short 6.93 million
- Shares Short Prior Month 6.44 million
- Short Ratio 2.66
- Short % of Float 8%
- Short % of Shares Outstanding 6%
Technicals
- Beta 1.1
- 52 Week High $5.7
- 52 Week Low $1.5
- 50 Day Moving Average 4.4
- 200 Day Moving Average 3.27
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Selecta Biosciences, Inc (SELB) Dividend Calendar:
Selecta Biosciences, Inc (SELB) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Selecta Biosciences, Inc (SELB) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Selecta Biosciences, Inc (SELB) Chart:
Selecta Biosciences, Inc (SELB) News:
Below you will find a list of latest news for Selecta Biosciences, Inc (SELB) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Selecta Biosciences, Inc (SELB) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest SELB Trades:
Selecta Biosciences, Inc (SELB) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-27 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-15 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-08 | 8-K (Current report) | |
| 2020-10-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-08 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-30 | 8-K (Current report) | |
| 2020-09-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-03 | 8-K (Current report) | |
| 2020-08-18 | D (Notice of Exempt Offering of Securities) | |
| 2020-08-14 | EFFECT (Notice of Effectiveness) | |
| 2020-08-12 | CORRESP (Correspondence) | |
| 2020-08-11 | UPLOAD (SEC-generated letter) | |
| 2020-08-10 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-06 | S-3 (Registration statement under Securities Act of 1933) | |
Selecta Biosciences, Inc (SELB) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Selecta Biosciences, Inc (SELB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2604%
Institutional Ownership: 6441%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-23 | Takashi Kei Kishimoto | Chief Scientific Officer | Buy | 30,000.00 | 2.77 | 83,100.00 | 126,149.00 | |
| 2020-10-23 | TIMOTHY A SPRINGER | Director | Buy | 994,488.00 | 2.71 | 2,699,736.57 | 14,480,948.00 | |
| 2020-10-22 | TIMOTHY A SPRINGER | Director | Buy | 1,770,204.00 | 2.63 | 4,656,698.64 | 13,486,460.00 | |
| 2020-10-21 | TIMOTHY A SPRINGER | Director | Buy | 880,000.00 | 2.50 | 2,199,472.00 | 11,716,256.00 | |
| 2020-10-20 | TIMOTHY A SPRINGER | Director | Buy | 910,000.00 | 2.21 | 2,013,193.00 | 10,836,256.00 | |
| 2020-10-19 | TIMOTHY A SPRINGER | Director | Buy | 759,500.00 | 2.36 | 1,795,002.30 | 9,926,256.00 | |
| 2020-10-16 | TIMOTHY A SPRINGER | Director | Buy | 218,196.00 | 2.42 | 528,034.32 | 9,166,756.00 | |
| 2020-10-09 | TIMOTHY A SPRINGER | Director | Buy | 276,703.00 | 2.00 | 552,465.21 | 8,948,560.00 | |
| 2020-10-08 | TIMOTHY A SPRINGER | Director | Buy | 530,441.00 | 1.89 | 1,000,836.08 | 8,671,857.00 | |
| 2020-10-07 | TIMOTHY A SPRINGER | Director | Buy | 654,953.00 | 1.65 | 1,078,576.60 | 8,141,416.00 | |
| 2020-10-06 | TIMOTHY C BARABE | Director | Buy | 50,000.00 | 1.68 | 83,985.00 | 171,013.00 | |
| 2020-10-06 | TIMOTHY A SPRINGER | Director | Buy | 2,000,000.00 | 1.68 | 3,365,800.00 | 7,486,463.00 | |
| 2020-09-02 | Carsten Brunn | President and CEO | Sell | 3,364.00 | 2.39 | 8,034.58 | 93,735.00 | |
| 2020-09-01 | Carsten Brunn | President and CEO | Buy | 10,937.00 | 97,099.00 | | ||
| 2020-06-24 | TIMOTHY C BARABE | Director | Buy | 32,840.00 | 1.46 | 47,946.40 | 121,013.00 | |
| 2020-06-02 | Carsten Brunn | President and CEO | Sell | 3,253.00 | 3.86 | 12,556.91 | 86,162.00 | |
| 2020-06-01 | Carsten Brunn | President and CEO | Buy | 10,938.00 | 89,415.00 | | ||
| 2020-03-17 | TIMOTHY C BARABE | Director | Buy | 5,000.00 | 2.00 | 10,000.00 | 88,173.00 | |
| 2020-03-03 | Carsten Brunn | President and CEO | Sell | 3,374.00 | 3.86 | 13,011.49 | 78,477.00 | |
| 2020-03-01 | Carsten Brunn | President and CEO | Buy | 10,937.00 | 81,851.00 | |